16:55 EST PTC Therapeutics falls 10% to $23.88 after CHMP negative opinion for Translarna
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PTCT:
- Citi opens ‘negative catalyst watch’ on PTC Therapeutics into EU decision
- PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference
- PTC Therapeutics sees FY24 revenue $600M-$850M, consensus $652.89M
- PTC Therapeutics announces 2024 potential key clinical, regulatory events
- PTC Therapeutics sees FY23 revenue about $946M, consensus $936.85M
